Results 21 to 30 of about 4,942 (259)
Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)
Pharmaceuticals, 2023 Dyslipidemia treatment is of major importance in reducing the risk of atherosclerotic cardiovascular disease (ASCVD), which is still the most common cause of death worldwide. During the last decade, a novel lipid-lowering drug category has emerged, i.e.,
Niki Katsiki +3 more
doaj +3 more sources
Endocrinology, Diabetes & MetabolismIntroduction Inclisiran, a small interfering RNA (siRNA), reduces the levels of low‐density lipoproteins (LDL) in the body by preventing the hepatic synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9). However, there is limited pooled data
Jawad Basit +9 more
doaj +2 more sources
Inclisiran for the treatment of hypercholesterolaemia
Drugs in ContextInclisiran is a synthetic small interfering RNA (siRNA) that inhibits the production of proprotein convertase subtilisin/ kexin 9 (PCSK9) in hepatocytes by silencing the translation of PCSK9 mRNA.
Joel C Marrs, Sarah L Anderson
doaj +3 more sources
Harnessing RNA Interference for Cholesterol Lowering: The Bench‐to‐Bedside Story of Inclisiran
Journal of the American Heart Association: Cardiovascular and Cerebrovascular DiseaseLowering low‐density lipoprotein cholesterol (LDL‐C) is a cornerstone of reducing risk for atherosclerotic cardiovascular disease. Despite the approval of nonstatin therapies for LDL‐C lowering over the past 2 decades, these medications are underused ...
Michael J. Wilkinson +3 more
doaj +2 more sources
Current usage of inclisiran for cardiovascular diseases: overview of current clinical trials
Frontiers in PharmacologyBackgroundCardiovascular diseases are predominant health conditions across the world due to their rising prevalence and association with several disorders.
Maan H. Harbi
doaj +2 more sources
pharma-kritik, 2021 Inclisiran: Inclisiran (Leqvio® ) besteht aus einer kleinen Ribonukleinsäure. Mit Inclisiran-Injektionen alle 6 Monate können die LDL-Cholesterinwerte um rund 50% gesenkt werden, weshalb es bei Personen verwendet werden kann, bei denen Statine nicht genügen oder nicht vertragen werden.
Jonathan Lappin, Andrea Llano
+4 more sources
THE POTENTIAL DANGER TO ASCVD RISK REDUCTION: A RARE CASE OF INCLISIRAN INDUCED VASCULITIS
American Journal of Preventive CardiologyTherapeutic Area: Pharmacologic Therapy Case Presentation: A 62-year-old male with coronary artery disease, hypertension, hyperlipidemia, and osteoarthritis complained of arthralgias, pharyngeal ulcers, ear fullness, and subjective fever.
Sumair Ozair, DO
doaj +2 more sources
Effects of Inclisiran, Alirocumab, Evolocumab, and Evinacumab on Lipids: A Network Meta-Analysis [PDF]
Reviews in cardiovascular medicineBackground: Direct comparisons between the drugs are limited, and the dosing remains debatable. Therefore, the study aims to indirectly compare the efficacy and safety of inclisiran, alirocumab, evolocumab, and evinacumab in lipid-lowering through a ...
Lin Zhang +5 more
openalex +2 more sources
Inclisiran and siRNA-Based Lipid Lowering: A New Frontier Including ANGPTL3 Inhibitors and Apo C III Inhibitors [PDF]
Indian Journal of Cardiovascular Disease in WomenCardiovascular (CV) disease remains the leading cause of death worldwide. Dyslipidemia is a well-known risk factor for CV disease. The persistent rise in heart disease despite widespread use of statins highlights the limitations of current cholesterol ...
Ramya Pechetty +4 more
openalex +2 more sources
ONE YEAR EXPERIENCE WITH INCLISIRAN IN AN ACADEMIC LIPID CLINIC:
American Journal of Preventive Cardiology, 2023 Therapeutic Area: Pharmacologic Therapy Background: Real-world data examining inclisiran use in US clinical practice are limited. We report a one-year experience with inclisiran in an academic lipid clinic. Methods: Retrospective chart review of patients
Tommy T. Chiou, BA +3 more
doaj +1 more source